Resaphene Suisse AG Company Profile
News Articles
Resaphene Suisse AG / Key word(s): Patent Resaphene Suisse AG: European Patent Office announces patent for tinnitus therapy 07-Dec-2018 / 21:54 CET/CEST Disclosure of an inside information acc...
DGAP-DD: Resaphene Suisse AG english
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 20.12.2018 / 16:45 The issuer is solely respon...
Resaphene Suisse AG: Breakthrough in Tinnitus Therapy
With publication in the specialist magazine for complementary medicine CO.med 06/2018 informed Johannes Ebbers from Düren (Germany) on the results of his clinical user observatio...
Credit Suisse: FDA won't approve Teva's migraine drug this month
Credit Suisse has downgraded Teva saying that the risk-reward ratio for an investment is unattractive.
Credit Suisse belässt Gerresheimer auf 'Outperform'
Die Schweizer Bank Credit Suisse hat die Einstufung für Gerresheimer nach Zahlen auf "Outperform" mit einem Kursziel von 82 Euro belassen. Die Jahreszahlen des Verpackungsspezialisten seien weitge...
Credit Suisse belässt Astrazeneca auf 'Outperform'
Die Schweizer Bank Credit Suisse hat die Einstufung für Astrazeneca nach Zahlen auf "Outperform" mit einem Kursziel von 6350 Pence belassen. Die Umsätze mit den wichtigsten Produkten des Pharmakon.....
Credit Suisse lässt Microsoft auf 'Outperform'
Die Schweizer Bank Credit Suisse hat die Einstufung für die Aktien des Softwarekonzerns Microsoft auf "Outperform" mit einem Kursziel von 125 US-Dollar belassen. Dies schrieb Analyst Brad Zelnick ...
Credit Suisse hebt Ziel für Astrazeneca - 'Outperform'
Die Schweizer Bank Credit Suisse hat das Kursziel für Astrazeneca von 5900 auf 6350 Pence angehoben und die Einstufung auf "Outperform" belassen. Analyst Matthew Weston passte in einer am Donnerst...
Drugs and Medications
These highlights do not include all the information needed to use LUMASON safely and effectively. See full prescribing information for LUMASON. LUMASON (sulfur hexafluoride lipid-type A microspheres) ...
Asacol (mesalamine) Delayed-Release Tablets
Clinical Trials
Background: It is known that postoperative malnutrition remains inevitable for gastric cancer patients with adjuvant chemotherapy, which could have prejudicial influence on the compliance ...
Companies
Resaphene Suisse AG was founded in 2015 with the aim of developing a tinnitus therapy device with funds from the incubator of BS Health Group AG. After the prototype was available...
Nil
We were one of the first investment banks to create specialized global industry groups, each dedicated to providing unmatched industry knowledge to its clients. Each industry is covered by senior prof...
Considering the vast impact caused by the emergence of the biotechnologies, and eager to play a driving role in these evolutions, BeFutur Biotechnologies and its subsidiaries have set up an exclusive ...
Renaissance Capital Milestones
Renaissance Capital, founded in 1991 and headquartered in Greenwich, CT, is the leading provider of independent research and investment management services focused on newly public companies. The Firm ...
More Information about "Resaphene Suisse AG" on BioPortfolio
We have published hundreds of Resaphene Suisse AG news stories on BioPortfolio along with dozens of Resaphene Suisse AG Clinical Trials and PubMed Articles about Resaphene Suisse AG for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Resaphene Suisse AG Companies in our database. You can also find out about relevant Resaphene Suisse AG Drugs and Medications on this site too.
